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Glucocorticoids are the first-line treatment for active mod-
erate-to-severe and sight-threatening Graves’ orbitopathy.
Glucocorticoid therapy, by exerting antiinflammatory and
immunomodulatory effects, reduces pain, injection and
edema of orbital tissues and provides a substantial relief
from optic nerve compression. Although efficiency of both
oral and intravenous glucocorticoids is proven, the rando-
mized clinical trials revealed that intravenous therapy is
more effective and better tolerated. However, 20-40% of
patients respond only partially or do not respond to immu-
nosuppressive treatment. The effectiveness of treatment
may be improved by proper selection of patients suspected
to have beneficial results, i.e. those with a high degree of
disease activity, with orbitopathy of recent onset or recent
progression. Corticotherapy may cause major side effects
which make treatment continuation impossible. Orbital
radiotherapy exerts nonspecific antiinflammatory effect
and suppresses radiosensitive lymphocytes infiltrating the
orbital space. Orbital radiotherapy remains an effective and
safe second-line treatment preferably used in association
with glucocorticoids. The combined therapy is more effec-
tive than either treatment alone. Sight-threatening Graves’
orbitopathy due to compressive optic neuropathy or cor-
neal ulceration requires immediate intervention. High-dose
daily intravenous glucocorticoids are the first-line treat-
ment and if the response is absent or poor within 1-2
weeks the orbital decompression should be performed.
Corneal breakdown should be additionally treated with
topical lubricants, and sometimes, to provide eyelid closure,
with blepharorraphy or tarsorraphy. Unsuccessful oral glu-
cocorticoid treatment of active Graves’ orbitopathy should
be an indication for orbital radiotherapy, preferably
combined with glucocorticoids, or to a 3 month intrave-
nous methylprednisolone course. If intravenous methyl-
prednisolone was the first treatment and the response is
not satisfactory, the intravenous course should be repeated
combined with orbital radiotherapy. An alternative
approach is combination of oral or intravenous glucocorti-
coids with cyclosporine for 3-6 months. It was demon-
strated that the combined treatment of cyclosporine with
oral glucocorticoids resulted in substantial improvement
and was useful to reduce the dose of glucocorticoids. In
steroid unresponsive Graves’ orbitopathy, biological agents
as anti-lymphocyte antibody (anti-CD 20, rituximab) and
anti-cytokine antibody (anti-TNFa, etanercept) have
shown promise. Theoretically somatostatin analogue pasir-
eotide, with a wider than octreotide or lanreotide binding
affinity for various somatostatin receptor subtypes could be
also a treatment option. As far as the randomized clinical
trials are not available, the use of biological agents and
somatostatin analogs is experimental. We hope that the
future treatment will be based on pathogenic mechanisms
of Graves’ orbitopathy. Small molecule “drug like” TSH
receptor neutral antagonists were shown to antagonize
TSAb activation of TSH receptor on retroorbital preadipo-
cytes and possibly could be used to treat Graves’ orbitopa-
thy. Currently their effects were determined in the model
of orbit cells.
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